I was trying to find out about Brazil results and ran into the initial dealings with the FDA when we got an eIND to treat patients and great success at Montefiore and the FDA just walked us right into a trial that took us out of the emergency room for a whole year only to attack us with that letter. Looking back, what a set up! And all those people we could have helped!

Quote:

---

n March 2020, 10 terminally ill, critical COVID-19 patients received two doses of leronlimab via individual emergency use indication. We analyzed changes in clinical presentation, immune cell populations, inflammation, as well as SARS-CoV-2 plasma viremia before and 14 days after treatment.
Results

Over the 14-day study period, six patients survived, two were extubated, and one discharged. We observed complete CCR5 receptor occupancy in all donors by day 7.

Quote:

---

---

---